Reports · for Medical strategy and insights teams
Understand how clinicians compare therapies, and where the comparison breaks down.
Clinicians compare constantly in public. The useful part is the reasoning, which a ranking would hide.
When you need it
- A competitor's readout or approval
- Positioning work before a launch
- A guideline update that reorders options
Ask your agent
“How do clinicians compare these two regimens in public, and what do they say prevents a direct comparison?”
More to ask
- “Which reports in polycythemia vera mention hydroxyurea as the comparator, and how do clinicians weigh it?”
- “What do clinicians say would change their choice between these two options?”
- “Summarize the competitor trial's report in five findings, keeping every caveat clinicians attach.”
Before and after
How the work changes
Today
- Read a competitive landscape built from press releases
- Hear how clinicians compare options only second-hand
- Treat a cross-trial comparison as settled because it is repeated
With Erudio
- Comparisons attributed to who made them, with the passage
- The boundaries clinicians name: population, comparator, endpoint
- One report per trial, so your trial and the competitor's read the same way
What you get
- Attributed comparisons clinicians make between therapies
- The reasons a direct ranking does not hold, stated plainly
- No efficacy verdicts and no consensus claims
Tools it calls
mcp
search_reports({ "indication": "<indication>" })
read_report({ "report_id": "<id>", "sections": ["findings"] })
search({ "query": "<drug A> versus <drug B>" })
fetch({ "ids": ["<result id>", "<result id>"] })In a published report
PROUD-PV
NCT01949805
How clinicians weigh PROUD-PV's interferon against hydroxyurea, ruxolitinib and rusfertide, and the limits they attach.
- F7Hydroxyurea remains a credible choice; interferon preference is shaped by time horizon, patient priorities and specific constraints
- F9Ruxolitinib is a symptom- and failure-driven alternative, with upfront positioning and long-exposure safety still questioned
- F10Rusfertide is discussed chiefly as an adjunct or bridge, not as a substitute for anticlonal treatment
What it does not do
- Cross-trial comparisons stay attributed to the clinician who made them.
- No efficacy verdicts and no consensus claims.
- Competitor commentary comes from public sources only.